Analyst at H.C. Wainwright Reiterated The Eyegate (EYEG) “Buy” Rating They’ve Had

February 22, 2018 - By Dolores Ford

 Analyst at H.C. Wainwright Reiterated The Eyegate (EYEG)

Eyegate (EYEG) Rating Reaffirmed

This Morning, Wednesday morning, Eyegate (EYEG)‘s “Buy” rating was reiterated by Analysts at H.C. Wainwright in an analyst report.

Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) Ratings Coverage

Among 2 analysts covering Eyegate Pharma… (EYEG), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Eyegate Pharma… has $600 highest and $3.0 lowest target. $3’s average target is 400.00% above currents $0.6 stock price. Eyegate Pharma… had 8 analyst reports since April 7, 2016 according to SRatingsIntel. H.C. Wainwright maintained the shares of EYEG in report on Tuesday, February 6 with “Buy” rating. The stock of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) has “Buy” rating given on Tuesday, December 19 by H.C. Wainwright. The stock of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) has “Buy” rating given on Wednesday, November 15 by H.C. Wainwright. The firm earned “Buy” rating on Thursday, April 7 by Noble Financial. The firm has “Buy” rating given on Wednesday, August 2 by H.C. Wainwright. On Tuesday, August 8 the stock rating was maintained by H.C. Wainwright with “Buy”. H.C. Wainwright maintained it with “Buy” rating and $600 target in Wednesday, June 14 report. H.C. Wainwright maintained Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) rating on Thursday, November 9. H.C. Wainwright has “Buy” rating and $6.0 target.

The stock 0.37% or $0 during the last trading session, reaching $0.6. It is down 40.33% since February 22, 2017 and is downtrending. It has underperformed by 57.03% the S&P500.

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye. The company has market cap of $10.32 million. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It currently has negative earnings. It is also developing the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial defects, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions.

More notable recent Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) news were published by: Globenewswire.com which released: “EyeGate Achieves 75% Enrollment in Pivotal Phase 3 Clinical Trial for Anterior …” on December 18, 2017, also Marketwatch.com with their article: “Eyegate Pharma stock surges 11% after receiving Valeant milestone payment” published on May 22, 2017, Globenewswire.com published: “EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract …” on February 05, 2018. More interesting news about Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) were released by: Streetinsider.com and their article: “Eyegate Pharma (EYEG) Reports New US Patent for Iontophoretic Delivery of …” published on December 19, 2017 as well as Globenewswire.com‘s news article titled: “EyeGate Receives Milestone Payment from Valeant Pharmaceuticals for EGP-437 …” with publication date: May 22, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: